ReviewAging clinical and experimental research2022
Improving vaccination rates in older adults and at-risk groups: focus on pertussis.
Review in Aging clinical and experimental research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases.Human vaccines & immunotherapeutics · 2023Pooled it
- Vaccinations in patients with interstitial lung diseases: a narrative review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- The Ongoing Challenge of Pertussis in Eastern and Northern Europe: Recommendations from the Global Pertussis Initiative.Infectious diseases and therapy · 2026Review
- Advancing Vaccination Strategies for Older Adults: Insights of the Adult Immunization Board Meeting.Drugs & aging · 2026Review
- Developing a Latin American Delphi Consensus on Vaccination for Respiratory Diseases in Older Adults.Annals of geriatric medicine and research · 2025Article
- The Burden of Pertussis Disease and Vaccination Coverage in Australian Adults Attending Primary Health Care.Vaccines · 2025Article
- Review
- Review
- Accessibility of pertussis vaccine immunization services in Hubei Province from a supply-demand coupling perspective.Frontiers in public health · 2025Article
- The 2024 resurgence ofFrontiers in public health · 2025Article
- Understanding the impact of adult pertussis and current approaches to vaccination: A narrative review and expert panel recommendations.Human vaccines & immunotherapeutics · 2024Review
- Public health management of pertussis in adults: Practical challenges and future strategies.Human vaccines & immunotherapeutics · 2024Review
- Real-Life Insights into Pertussis Diagnosis: High Yield of PCR Testing and Clinical Outcomes-An Emerging Old Enemy or Just a Sign of PCR Times?Journal of personalized medicine · 2024Article
- Assessing the Underestimation of Adult Pertussis Disease in Five Latin American Countries.Infectious diseases and therapy · 2023Article
- Coping Strategies for Pertussis Resurgence.Vaccines · 2023Review
- Coverage rates for diphtheria, tetanus, poliomyelitis, and pertussis age-specific booster recommendations in France: 2018 update of the real-world cohort analysis.Infectious medicine · 2023Article
- Descriptive Overview of Pertussis Epidemiology Among Older Adults in Europe During 2010-2020.Infectious diseases and therapy · 2022Article
- Article
- Adaptive immune response to bordetella pertussis during vaccination and infection: emerging perspectives and unanswered questions.Expert review of vaccinesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the implementation of effective paediatric vaccination programmes, pertussis remains a global health problem. Disease epidemiology has changed over time, shifting towards the adolescent and adult populations. In adults, the true burden of pertussis is greatly underestimated and pertussis vaccine coverage rates are suboptimal, including individuals with chronic conditions. Here, we report the outcomes of a virtual international scientific workshop to assess the evidence on the burden of pertussis in older adults and identify potential solutions to improve uptake of pertussis vaccines. In adults, pertussis is underdiagnosed in part due to atypical or milder clinical presentation and the lack of testing and case confirmation. However, contemporary epidemiological data denoted an increase in the burden of pertussis among adolescents and adults. This might be related to a variety of reasons including the waning of immunity over time, the lack of booster vaccination, and the improved diagnostic methods that led to increased recognition of the disease in adults. Pertussis sequelae can be severe in older adults, particularly those with existing chronic medical conditions, and the vulnerability of these groups is further enhanced by low pertussis vaccine coverage. Possible measures to increase vaccine uptake include strengthening and harmonisation of immunisation guidelines, healthcare professionals taking a more active role in recommending pertussis vaccination, involvement of vaccination centres and pharmacies in the vaccination process, and improving knowledge of pertussis burden and vaccine efficacy among the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.